KRAS wild-type
|
Ovarian Cancer
|
KRAS wild-type
|
Ovarian Cancer
|
VS-6766 + VS-6063 Sensitive: B - Late Trials
|
VS-6766 + VS-6063 Sensitive: B - Late Trials
|
KRAS wild-type
|
Pancreatic Ductal Adenocarcinoma
|
KRAS wild-type
|
Pancreatic Ductal Adenocarcinoma
|
gemcitabine + albumin-bound paclitaxel Sensitive: B - Late Trials
|
gemcitabine + albumin-bound paclitaxel Sensitive: B - Late Trials
|
KRAS wild-type
|
Pancreatic Ductal Adenocarcinoma
|
KRAS wild-type
|
Pancreatic Ductal Adenocarcinoma
|
5-fluorouracil + oxaliplatin Sensitive: B - Late Trials
|
5-fluorouracil + oxaliplatin Sensitive: B - Late Trials
|
KRAS wild-type
|
CRC
|
KRAS wild-type
|
CRC
|
cetuximab + palbociclib Sensitive: C2 – Inclusion Criteria
|
cetuximab + palbociclib Sensitive: C2 – Inclusion Criteria
|
KRAS wild-type
|
CRC
|
KRAS wild-type
|
CRC
|
cetuximab Sensitive: C2 – Inclusion Criteria
|
cetuximab Sensitive: C2 – Inclusion Criteria
|
KRAS wild-type
|
CRC
|
KRAS wild-type
|
CRC
|
bevacizumab Sensitive: C2 – Inclusion Criteria
|
bevacizumab Sensitive: C2 – Inclusion Criteria
|
KRAS wild-type
|
Biliary Tract Cancer
|
KRAS wild-type
|
Biliary Tract Cancer
|
panitumumab Sensitive: C2 – Inclusion Criteria
|
panitumumab Sensitive: C2 – Inclusion Criteria
|
KRAS wild-type
|
CRC
|
KRAS wild-type
|
CRC
|
cetuximab Resistant: C3 – Early Trials
|
cetuximab Resistant: C3 – Early Trials
|
KRAS wild-type
|
CRC
|
KRAS wild-type
|
CRC
|
panitumumab + cabozantinib tablet Sensitive: C3 – Early Trials
|
panitumumab + cabozantinib tablet Sensitive: C3 – Early Trials
|
KRAS wild-type
|
CRC
|
KRAS wild-type
|
CRC
|
SIRB Sensitive: C3 – Early Trials
|
SIRB Sensitive: C3 – Early Trials
|
KRAS wild-type
|
CRC
|
KRAS wild-type
|
CRC
|
MM-121 Sensitive: D – Preclinical
|
MM-121 Sensitive: D – Preclinical
|